APRI (Aprinoia Therapeutics) Minority Interest: $0.00 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Minority Interest?

Aprinoia Therapeutics APRI Minority Interest is $0.00 Mil as of Dec. 2023.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Aprinoia Therapeutics's minority interest for the quarter that ended in Dec. 2023 was $0.00 Mil.

Aprinoia Therapeutics Minority Interest Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Minority Interest Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Minority Interest
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Minority Interest 0.00 0.00 0.00 0.00 0.00

Aprinoia Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of $0.00 Mil mean?
Aprinoia Therapeutics (APRI) has a Minority Interest of $0.00 Mil as of Dec. 2023. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Aprinoia Therapeutics.
Is Aprinoia Therapeutics' Minority Interest too high?
Aprinoia Therapeutics' current Minority Interest is $0.00 Mil.
How does Aprinoia Therapeutics' Minority Interest compare to ?
Aprinoia Therapeutics' Minority Interest of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Aprinoia Therapeutics. Aprinoia Therapeutics's current Minority Interest is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Minority Interest of $0.00 Mil. The current Minority Interest is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Minority Interest is $0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.